Literature DB >> 1934334

Relation between ventricular and myocyte remodeling with the development and regression of supraventricular tachycardia-induced cardiomyopathy.

F G Spinale1, J L Zellner, M Tomita, F A Crawford, M R Zile.   

Abstract

Chronic supraventricular tachycardia (SVT) causes left ventricular (LV) dilatation and dysfunction. Termination of SVT appears to reduce LV size and improve function. However, changes in myocyte structure and morphology that accompany the development and regression of SVT-induced cardiomyopathy have not been studied. Accordingly, we measured LV function using echocardiography and catheterization in three groups of six pigs each: 3 weeks of atrial pacing (SVT; 240 beats/min), 4-week recovery from SVT (PST), and sham-operated controls. At each of these three end points, isolated myocyte dimensions and nuclear number were measured using fluorescence, and the volume percent of myocytes and myofibrils was computed from tissue sections using stereological techniques. SVT resulted in reduced LV fractional shortening (15 +/- 3% versus 31 +/- 2%, p less than 0.05), increased end-diastolic dimension (5.6 +/- 0.8 versus 3.8 +/- 0.2 cm, p less than 0.05), and no change in mass (2.6 +/- 0.1 versus 2.6 +/- 0.2 g/kg, p = NS) compared with controls. Myocyte length significantly increased with SVT (171 +/- 9 versus 109 +/- 11 microns, p less than 0.05), without significant changes in cell width (28 +/- 2 versus 26 +/- 2 microns). Nuclear number did not change with SVT; however, nuclear area/myocyte area significantly increased compared with controls (9.5 +/- 0.8 versus 8.7 +/- 0.8 x 10(-2), p less than 0.05). The volume percent of myocytes within the ventricular wall and the volume percent of myofibrils within myocytes decreased with SVT compared with controls (72 +/- 3% versus 80 +/- 3% and 45 +/- 5% versus 63 +/- 4%, respectively, p less than 0.05), with no change in total myocyte volume (54.2 +/- 2.7 versus 54.3 +/- 1.8 microns3 x 10(12)). In the PST group, LV fractional shortening returned to control values; however, there was persistent dilatation (end-diastolic dimension: 4.2 +/- 0.1 cm, p less than 0.05), and LV hypertrophy developed (3.3 +/- 0.3 g/kg, p less than 0.05). Increased myocyte length (158 +/- 5 microns, p less than 0.05) and width (33 +/- 2 microns, p less than 0.05) were observed in the PST group. The volume percent of myocytes and myofibrils returned to control values, with total myocyte volume significantly increased in the PST group compared with the control and SVT groups (74.5 +/- 2.6 microns3 x 10(12), p less than 0.05). In addition, the number of nuclei per myocyte in the PST group significantly increased from control values (5.1 +/- 0.1 versus 4.0 +/- 0.1, p less than 0.05).(ABSTRACT TRUNCATED AT 400 WORDS)

Entities:  

Mesh:

Year:  1991        PMID: 1934334     DOI: 10.1161/01.res.69.4.1058

Source DB:  PubMed          Journal:  Circ Res        ISSN: 0009-7330            Impact factor:   17.367


  18 in total

1.  Left ventricular systolic dysfunction induced by ventricular ectopy: a novel model for premature ventricular contraction-induced cardiomyopathy.

Authors:  Jose F Huizar; Karoly Kaszala; Jonathan Potfay; Anthony J Minisi; Edward J Lesnefsky; Antonio Abbate; Eleonora Mezzaroma; Qun Chen; Rakesh C Kukreja; Nicholas N Hoke; Leroy R Thacker; Kenneth A Ellenbogen; Mark A Wood
Journal:  Circ Arrhythm Electrophysiol       Date:  2011-05-16

2.  Infarct size reduction and attenuation of global left ventricular remodeling with the CorCap cardiac support device following acute myocardial infarction in sheep.

Authors:  Aaron S Blom; James J Pilla; Robert C Gorman; Joseph H Gorman; Rupak Mukherjee; Francis G Spinale; Michael A Acker
Journal:  Heart Fail Rev       Date:  2005-06       Impact factor: 4.214

3.  Mechanical characteristics of tachycardia-induced left-ventricular failure as evaluated in isolated dog hearts.

Authors:  Z Wang; W D Denney; L K Taylor; D M Regen; D E Hansen
Journal:  Heart Vessels       Date:  1995       Impact factor: 2.037

Review 4.  Heart failure in children in tropical regions.

Authors:  Manojkumar Rohit; Ankur Gupta; K K Talwar
Journal:  Curr Heart Fail Rep       Date:  2013-12

5.  [Temporary mechanical left heart support. Recovery of heart function in patients with end-stage idiopathic dilated cardiomyopathy].

Authors:  J Müller; G Wallukat; Y G Weng; M Dandel; S Spiegelsberger; S Semrau; K Brandes; H Bieda; M Hummel; M Loebe; R Meyer; R Hetzer
Journal:  Herz       Date:  1997-10       Impact factor: 1.443

6.  Recovery pattern of left ventricular dysfunction following radiofrequency ablation of incessant supraventricular tachycardia in infants and children.

Authors:  J V De Giovanni; A Dindar; M J Griffith; R A Edgar; E D Silove; O Stumper; J G Wright
Journal:  Heart       Date:  1998-06       Impact factor: 5.994

7.  Neonatal cardiomyopathy in mice homozygous for the Arg403Gln mutation in the alpha cardiac myosin heavy chain gene.

Authors:  D Fatkin; M E Christe; O Aristizabal; B K McConnell; S Srinivasan; F J Schoen; C E Seidman; D H Turnbull; J G Seidman
Journal:  J Clin Invest       Date:  1999-01       Impact factor: 14.808

8.  Downregulation of cardiac guanosine 5'-triphosphate-binding proteins in right atrium and left ventricle in pacing-induced congestive heart failure.

Authors:  D A Roth; K Urasawa; G A Helmer; H K Hammond
Journal:  J Clin Invest       Date:  1993-03       Impact factor: 14.808

9.  Effects of chronic beta-adrenergic blockade on the left ventricular and cardiocyte abnormalities of chronic canine mitral regurgitation.

Authors:  H Tsutsui; F G Spinale; M Nagatsu; P G Schmid; K Ishihara; G DeFreyte; G Cooper; B A Carabello
Journal:  J Clin Invest       Date:  1994-06       Impact factor: 14.808

10.  Reduced 3H-ouabain binding site (Na,K-ATPase) concentration in ventricular myocardium of dogs with tachycardia induced heart failure.

Authors:  T A Schmidt; J S Larsen; R P Shannon; K Komamura; D E Vatner; K Kjeldsen
Journal:  Basic Res Cardiol       Date:  1993 Nov-Dec       Impact factor: 17.165

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.